GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Bellevue Life Sciences Acquisition Corp (NAS:BLAC) » Definitions » Other Net Income (Loss)

Bellevue Life Sciences Acquisition (Bellevue Life Sciences Acquisition) Other Net Income (Loss) : $-0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Bellevue Life Sciences Acquisition Other Net Income (Loss)?

Bellevue Life Sciences Acquisition's Other Net Income (Loss) for the three months ended in Dec. 2023 was $0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.00 Mil.

Bellevue Life Sciences Acquisition's quarterly Other Net Income (Loss) increased from Jun. 2023 ($-0.00 Mil) to Sep. 2023 ($0.00 Mil) but then declined from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($0.00 Mil).

Bellevue Life Sciences Acquisition's annual Other Net Income (Loss) stayed the same from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil).

Bellevue Life Sciences Acquisition Other Net Income (Loss) Historical Data

The historical data trend for Bellevue Life Sciences Acquisition's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellevue Life Sciences Acquisition Other Net Income (Loss) Chart

Bellevue Life Sciences Acquisition Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Other Net Income (Loss)
- - - -

Bellevue Life Sciences Acquisition Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Bellevue Life Sciences Acquisition Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bellevue Life Sciences Acquisition Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Bellevue Life Sciences Acquisition's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Bellevue Life Sciences Acquisition (Bellevue Life Sciences Acquisition) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Bellevue Life Sciences Acquisition Corp (NAS:BLAC) » Definitions » Other Net Income (Loss)
Comparable Companies
ADEX NBST RWOD PMGM QDRO ONYX BOWN MSSA TBMC VII PBAJ SVMB SCRM CVII AAC GHIX ALCC AACT DWAC SAGA
Traded in Other Exchanges
N/A
Address
10900 NE 4th Street, Suite 2300, Bellevue, WA, USA, 98004
Website
Bellevue Life Sciences Acquisition Corp is a blank check company.
Executives
David Jin Yoo officer: Chief Financial Officer (135-270) 7TH FLOOR, SOFTFORUM B/D., 545-7 DOGOKDONG, GANGNAM, SEOUL M5 135-170
Kuk Hyoun Hwang director, 10 percent owner, officer: Chief Executive Officer 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Bellevue Global Life Science Investors Llc 10 percent owner 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Steven Reed other: Director Nominee 2843-122 PL. N.E., BELLEVUE WA 98005
In Chul Chung other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Hosun Euh other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Jin Whan Park other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Jun Chul Whang director 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Rad Roberts other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004